Initial results from Novo Nordisk’s STEP Young study show promising potential for semaglutide to reduce obesity in children, sparking renewed debate over early intervention and safety concerns.
Novo Nordisk’s first topline data from its STEP Young study suggest that semaglutide may offer a meaningful new option for some children with obesity, a condition that can have serious physical and emotional consequences. The company said 40.4% of children aged six to under 12 who received the drug for 68 weeks, alongside dietary changes, exercise and behavioural support, moved below the obesity threshold. In the placebo group, none did. That makes the result notable not only for its size, but also because childhood obesity treatment has a long history of disappointing results. Novo Nordisk has presented the findings as an important step forward, although the data have not yet been peer reviewed.
The trial enrolled 165 children, so the findings remain early and should be interpreted with caution. Even so, the result matters because obesity in childhood is not just a number on a chart. Mayo Clinic and Cleveland Clinic both note that childhood obesity is linked to later risks including type 2 diabetes, high blood pressure and abnormal cholesterol, while the condition can also affect self-esteem and quality of life during the school years. The hope, reflected in the STEP Young data, is that moving a child’s weight trajectory in a healthier direction early could reduce both immediate distress and long-term illness.
The prospect of using an anti-obesity medicine in younger children is likely to draw scrutiny, particularly over safety. Questions remain about whether treatment could affect growth, puberty, development or mental health, and whether it might contribute to disordered eating. Those concerns will need careful follow-up in larger, longer studies. But supporters argue that the same principle used in other paediatric conditions applies here: if a child’s condition crosses a threshold known to predict harm, waiting for damage to appear is not always the most responsible approach.
That broader argument is why the STEP Young findings could become part of a larger debate about how medicine should respond to childhood obesity. Critics are likely to question whether drug treatment is the right path for such young patients, while others will see it as a long-overdue acknowledgement that diet and counselling alone have often failed to deliver durable results. For families confronting severe obesity, the new data offer at least the possibility of another tool, one that may prove especially important if future studies confirm both effectiveness and safety.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
